Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
PLoS One. 2011 Apr 29;6(4):e14809. doi: 10.1371/journal.pone.0014809.
The National Avian Influenza Surveillance (NAIS) system detected human H5N1 cases in Thailand from 2004-2006. Using NAIS data, we identified risk factors for death among H5N1 cases and described differences between H5N1 and human (seasonal) influenza cases.
NAIS identified 11,641 suspect H5N1 cases (e.g. persons with fever and respiratory symptoms or pneumonia, and exposure to sick or dead poultry). All suspect H5N1 cases were tested with polymerase chain reaction (PCR) assays for influenza A(H5N1) and human influenza viruses. NAIS detected 25 H5N1 and 2074 human influenza cases; 17 (68%) and 22 (1%) were fatal, respectively. We collected detailed information from medical records on all H5N1 cases, all fatal human influenza cases, and a sampled subset of 230 hospitalized non-fatal human influenza cases drawn from provinces with ≥1 H5N1 case or human influenza fatality. Fatal versus non-fatal H5N1 cases were more likely to present with low white blood cell (p = 0.05), lymphocyte (p<0.02), and platelet counts (p<0.01); have elevated liver enzymes (p = 0.05); and progress to circulatory (p<0.001) and respiratory failure (p<0.001). There were no differences in age, medical conditions, or antiviral treatment between fatal and non-fatal H5N1 cases. Compared to a sample of human influenza cases, all H5N1 cases had direct exposure to sick or dead birds (60% vs. 100%, p<0.05). Fatal H5N1 and fatal human influenza cases were similar clinically except that fatal H5N1 cases more commonly: had fever (p<0.001), vomiting (p<0.01), low white blood cell counts (p<0.01), received oseltamivir (71% vs. 23%, p<.001), but less often had ≥1 chronic medical conditions (p<0.001).
In the absence of diagnostic testing during an influenza A(H5N1) epizootic, a few epidemiologic, clinical, and laboratory findings might provide clues to help target H5N1 control efforts. Severe human influenza and H5N1 cases were clinically similar, and both would benefit from early antiviral treatment.
国家禽流感监测系统(NAIS)在 2004-2006 年期间在泰国检测到人类 H5N1 病例。利用 NAIS 数据,我们确定了 H5N1 病例死亡的危险因素,并描述了 H5N1 与人类(季节性)流感病例之间的差异。
NAIS 确定了 11641 例疑似 H5N1 病例(例如有发热和呼吸道症状或肺炎且接触过病禽或死禽的人)。所有疑似 H5N1 病例均采用聚合酶链反应(PCR)检测流感 A(H5N1)和人类流感病毒。NAIS 检测到 25 例 H5N1 和 2074 例人类流感病例;分别有 17 例(68%)和 22 例(1%)死亡。我们从所有 H5N1 病例、所有致命性人类流感病例以及从有≥1 例 H5N1 病例或人类流感死亡病例的省份抽取的 230 例住院非致命性人类流感病例的样本中收集了详细的病历信息。与非致命性 H5N1 病例相比,致命性 H5N1 病例更可能出现白细胞(p=0.05)、淋巴细胞(p<0.02)和血小板计数(p<0.01)降低;肝酶升高(p=0.05);并进展为循环衰竭(p<0.001)和呼吸衰竭(p<0.001)。致命性和非致命性 H5N1 病例在年龄、医疗条件或抗病毒治疗方面无差异。与人类流感病例样本相比,所有 H5N1 病例均有直接接触病禽或死禽的经历(60%对 100%,p<0.05)。致命性 H5N1 和致命性人类流感病例在临床方面相似,但致命性 H5N1 病例更常见:发热(p<0.001)、呕吐(p<0.01)、白细胞计数降低(p<0.01)、接受奥司他韦治疗(71%对 23%,p<.001),但更常见无≥1 种慢性医疗条件(p<0.001)。
在禽流感 A(H5N1)流行期间缺乏诊断检测时,一些流行病学、临床和实验室发现可能有助于确定 H5N1 控制工作的重点。严重的人类流感和 H5N1 病例在临床上相似,两者都将受益于早期抗病毒治疗。